Compared to the nebulized group alone or the oral PFD group, the combined treatment group showed a significant improvement in PF by accelerating alveolar re-epithelialization, as determined by an increase in the ratio of aquaporin 5 (AQP5) to SP-C [123]. Here, AQP5 is linked to polyostotic fibrous dysplasia.